^
Association details:
| Biomarker: | EGFR mutation + TP53 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Ameile (aumolertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results
Published date:
08/08/2023
Excerpt:
The median age was 65 years (ranged 32-84), 59.7 % were female, 85.5 % received aumolertinib monotherapy, 14.5 % received aumolertinib combination therapy (bevacizumab or pemetrexed). ORR and DCR in patients receiving aumolertinib monotherapy were 66 % and 96.2 %, respectively...Meanwhile, aumolertinib combination therapy showed superior antitumor activity, ORR and DCR were 88.9 % and 100 %, respectively, and PFS rate at 24 months was 56.3% (Efficacy; Table)...Aumolertinib monotherapy or combination therapy showed excellent and encouraging results in EGFR-mutant NSCLC patients with co-mutations.
Secondary therapy:
pemetrexed
Source:
Title:
370P - Outcomes in patients with EGFR-mutant locally advanced or metastatic NSCLC co-mutations receiving aumolertinib as first-line treatment: A retrospective study
Published date:
11/28/2022
Excerpt:
We retrospectively collected data from 52 EGFR-mutant NSCLC patients with co-mutations...In the subgroup analysis of genotypes, ORR and DCR was 71.4 % and 100 % in TP53 mutation, 72.4 % and 100 % in cell cycle signaling pathway related genes, 66.7 % and 100 % in PIK3CA co-mutation, 83.3 % and 97.7 % in PD-L1 TPS 0-1, 55.6 % and 100 % in PD-L1 TPS ≥ 1...
